Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003118888 | SCV003787500 | uncertain significance | DiGeorge syndrome | 2022-08-19 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with TBX1-related conditions. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamic acid, which is acidic and polar, with aspartic acid, which is acidic and polar, at codon 409 of the TBX1 protein (p.Glu409Asp). |
Ambry Genetics | RCV004245894 | SCV005030272 | uncertain significance | Cardiovascular phenotype | 2023-12-11 | criteria provided, single submitter | clinical testing | The p.E409D variant (also known as c.1227G>T), located in coding exon 8 of the TBX1 gene, results from a G to T substitution at nucleotide position 1227. The glutamic acid at codon 409 is replaced by aspartic acid, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |